For citations:
Feist E, Fatenejad S, Grishin S, Korneva E, Luggen M, Nasonov E, Samsonov M, Smolen J, Fleischmann R. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2023;17(2):23-26. (In Russ.) https://doi.org/10.14412/1996-7012-2023-2-23-36
Email this article 